A New Alliance to Serve Patients in Japan

Amgen Astellas BioPharma KK

Robert A. Bradway
Chairman and CEO
Amgen

Yoshihiko Hatanaka
President and CEO
Astellas Pharma Inc.

Astellas Pharma: Cautionary Statement Regarding Forward-Looking Information

This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties.

Actual financial results may differ materially depending on a number of factors including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new products effectively, interruptions in production, infringements of the company’s intellectual property rights and the adverse outcome of material litigation.

This material contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations nor provide medical advice of any kind.
A New Alliance to Serve Patients in Japan

Yoshihiko Hatanaka
President and CEO
Astellas Pharma Inc.

Amgen and Astellas
Strategic Alliance for the Japanese Market

Long-term collaboration

Establish Joint Venture Company
Amgen Astellas BioPharma KK
About Astellas

1. Focus on innovative pharmaceutical business
   Urology, Transplantation, Oncology, Immunology & Infectious Diseases, Neurosciences and DM Complications and Kidney Diseases

2. Solid foundation in domestic sales
   The second largest share in Japan

3. Global expansion
   Own sales network in about 50 countries

4. Strong R&D capabilities
   Abundance of new pipeline candidates

Strategic Alliance: Structure

Amgen Astellas BioPharma KK

Long-term collaboration
Co-development & Co-commercialization

49% ownership of shares

51% ownership of shares

5 pipeline medicines
Strategic Alliance: Structure (continued)

Co-development & co-commercialization of 5 pipeline medicines

Amgen Astellas BioPharma KK

to become a wholly owned Amgen affiliate as soon as 2020

to be, on a product-by-product basis, in place until 2032 at the latest

2020 2032

Five Pipeline Medicines in Alliance

• New medicines, primarily biologics aimed at unmet medical needs in Japan

• Two medicines in late stage clinical trials in Japan

Hyperlipidemia
AMG 145 (P-2)

Osteoporosis
AMG 785 (P-2/3)

Cancer
AMG 102 (P-1)
AMG 337
AMG 103

AMG 102 (P-1)
AMG 337
AMG 103
Concept of Strategic Alliance

- Leverage strengths of both companies
- A win-win relationship
- Successful track records of alliances
- In-depth knowledge of local medical needs
- Long experience of development, regulatory affairs, and marketing in Japan
- Solid business foundation

Rapid delivery of innovative medicines to patients in Japan

Strategic Significance for Astellas

- Expand product portfolio in Japan
- Strengthen existing franchise in Japan
- Ensure sufficient investment in late-stage clinical pipeline

Hyperlipidemia
AMG 145
(P-2)

Osteoporosis
AMG 785
(P-2/3)

Cancer
AMG 102
(P-1)
AMG 337
AMG 103

The Third GCL = Focus Area

Existing Franchise
Amgen Forward Looking Statement

This presentation contains forward-looking statements that are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements about estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen’s most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen’s most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of May 29, 2013 and expressly disclaims any duty to update information contained in this presentation.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company’s results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others’ regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after we are on the market. Our business may be impacted by government investigations, litigation and products liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

This presentation includes GAAP and non-GAAP financial measures. In accordance with the requirements of SEC Regulation G, reconciliations between these two measures, if these slides are in hard copy, accompany the hard copy presentation or, if these slides are delivered electronically, are available on the Company’s website at www.amgen.com within the Investors section.

A New Alliance to Serve Patients in Japan

Robert A. Bradway
Chairman and CEO
Amgen
Amgen: Unlocking the Potential of Biology for Patients

- Serious illnesses
- Large unmet needs
- Biology first
Amgen: Unlocking the Potential of Biology for Patients

- Pioneering research
- Innovative medicines
- World-class manufacturing

Amgen Astellas Alliance

- Patient-focused
- Complementary capabilities
- Medicines to address unmet medical needs in Japan
## Amgen Astellas Alliance

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Lead Indication</th>
<th>Mode of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMG 145</td>
<td>Hyperlipidemia</td>
<td>Anti-PCSK-9 mAb</td>
</tr>
<tr>
<td>Romosozumab*</td>
<td>Osteoporosis</td>
<td>Anti-Sclerostin mAb</td>
</tr>
<tr>
<td>(AMG 785)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rilotumumab</td>
<td>Gastric cancer</td>
<td>Anti-HGF mAb</td>
</tr>
<tr>
<td>(AMG 102)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMG 337</td>
<td>Gastric cancer</td>
<td>MET inhibitor</td>
</tr>
<tr>
<td>Blinatumomab</td>
<td>Acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL)</td>
<td>Anti-CD19 BiTE*</td>
</tr>
<tr>
<td>(AMG 103)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Developed in collaboration with UCB

---

## Hyperlipidemia

**AMG 145**

- Human monoclonal antibody
- Anti-PCSK-9 mAb
Osteoporosis

*Romosozumab (AMG 785)*

- Human monoclonal antibody
- Anti-Sclerostin mAb

Gastric Cancer

*Rilotumumab (AMG 102)*

- Human monoclonal antibody
- Anti-HGF mAb

**AMG 337**

- Small molecule
- MET inhibitor
Acute Lymphoblastic Leukemia/Non-Hodgkin’s Lymphoma

Blinatumomab (AMG 103)

- Bispecific antibody
- Anti-CD19 BiTE®

Delivering important medicines to patients in Japan fighting serious illnesses

AMGEN

Astellas